

5. Cho, H., Weber, M.L., Shah, C.P. et al.: Initial utilization of aflibercept in exudative age related macular degeneration. Eur J Ophthalmol, 24(4); 2014: 576–581.
6. Martin, D.F., Maguire, M.G., Ying, G.S. et al.: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med, 364(20); 2011: 1897–1908.
7. Papadopoulos, N., Martin, J., Ruan, Q. et al.: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15(2); 2012: 171–185.
8. Resnikoff, S., Pascolini, D., Etya'ale, D. et al.: Global data on visual impairment in the year 2002, Bull World Health Organ, 82(11); 2004: 844–851.
9. Rudge, J.S., Holash, J., Hylton, D. et al.: VEGF Trap complex formation measu-
- res production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A, 104(47); 2007: 18363–18370.
10. Sawa, Y. et al.: Short-term outcomes of aflibercept for recurrent neovascular age-related macular degeneration in Japanese patients. E-poster PO-1531, World Ophthalmology Congress 2014, Tokyo, Japan, April 2–6, 2014.
11. Schmidt-Erfurth, U. et al.: Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology, 121; 2014: 193–201.
12. Schmier, J.K., Jones, M.L., Halpern, M.T.: The burden of age-related macular degeneration. Pharmacoeconomics, 24(4); 2006: 319–334.
13. Soubrane, G., Cruess, A., Lotery, A. et al.: Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol, 125(9); 2007: 1249–1254.
14. Eylea (aflibercept injekčný roztok v liekovke) Súhrn charakteristických vlastností lieku. Berlin, Nemecko: Bayer Pharma AG: 2014.
15. Wykoff, C.C., Brown, D.M., Maldonado, M.E. et al.: Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol, 98(7); 2014: 951–955.
16. Yonekawa, Y., Andreoli, C., Miller, J.B. et al.: Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol, 156(1); 2013: 29–35.

OZNÁMENÍ



Dovolujeme si Vám oznámit, že dne 26. 3. 2015 byla v Tereziánském sále Břevnovského kláštera slavnostně pasována na Rytířku českého lékařského stavu paní MUDr. Jaroslava Vladýková, DrSc. Vedle pana prof. MUDr. Ivana Karla, DrSc., je druhým oftalmologem, kterému byla tato vysoká pocta udělena.

Redakce časopisu